

Combinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation

Major subgroups according to the World Health Organisation (WHO) Classification	Initial diagnosis	Morphology code of the first HM	Major WHO subgroups and morphology codes probably referring to the same tumour as the first HM (see note 3)	Major WHO subgroups and morphology codes referring to potential transformation of the first HM (see note 3)
Myeloproliferative neoplasms (MPN)	Mast cell sarcoma	9740/3	Other MPN (excl. 9742/3)	9742/3, 9741/3
	Systemic mastocytosis	9741/3	See note 1	9742/3, 9741/3, AML (particularly if SM-AHNMD)
	Mast cell leukaemia	9742/3	Other MPN, 9800/3, 9860/3 (see also note 1)	
	Chronic myeloid leukaemia, NOS	<u>9863/3</u>	Other MPN, 9800/3, 9860/3, 9876/3, 9945/3, 9946/3, 9975/3	AML, 9811/3–9818/3, 9835/3–9837/3, 9801/3–9809/3
	Chronic myeloid leukaemia, BCR-ABL1 positive	9875/3	Other MPN, 9800/3, 9860/3	AML, 9811/3–9818/3, 9835/3–9837/3, 9801/3–9809/3
	Polycythaemia vera	9950/3	Other MPN	MDS, AML, 9801/3–9809/3
	Myeloproliferative neoplasm, NOS	<u>9960/3</u>	Other MPN, MD/MPN	MDS, AML, 9801/3–9809/3
	Primary myelofibrosis	<u>9961/3</u>	Other MPN, 9931/3	AML (excl 9931), 9801/3–9809/3
	Essential thrombocytaemia	<u>9962/3</u>	Other MPN	MDS, AML, 9801/3–9809/3
	Chronic neutrophilic leukaemia	<u>9963/3</u>	Other MPN, 9800/3, 9860/3	AML, 9801/3–9809/3
	Chronic eosinophilic leukaemia, NOS	<u>9964/3</u>	Other MPN, 9800/3, 9860/3, 9965/3, 9966/3, 9967/3	AML, 9801/3–9809/3
Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1 (MNLE)	Myeloid and lymphoid neoplasms with PDGFRA rearrangement	9965/3	MPN, 9800/3, 9820/3, 9860/3, 9964/3,	AML, 9801/3–9809/3
	Myeloid neoplasms with PDGFRB rearrangement	9966/3	MPN, 9800/3, 9820/3, 9860/3, 9964/3,	AML, 9801/3–9809/3
	Myeloid and lymphoid neoplasms with FGFR1 rearrangement	9967/3	MPN, PLN, 9800/3, 9820/3, 9860/3, 9964/3	AML, 9801/3–9809/3
Myelodysplastic/myeloproliferative neoplasms (MD/MPN)	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	9876/3	Other MD/MPN, MDS, MPN; 9800/3, 9860/3, 9863/3, 9960/3	AML, 9801/3–9809/3
	Chronic myelomonocytic leukaemia	9945/3	Other MD/MPN, MDS, 9800/3, 9860/3, 9863/3, 9960/3	AML, 9801/3–9809/3
	Juvenile myelomonocytic leukaemia	9946/3	Other MD/MPN, MDS, 9800/3, 9860/3, 9863/3, 9960/3	AML, 9801/3–9809/3
	Myelodysplastic/myeloproliferative neoplasm, unclassifiable	<u>9975/3</u>	Other MD/MPN, MDS, MPN	AML, 9801/3–9809/3
Myelodysplastic syndromes (MDS)	Refractory anaemia	9980/3	Other MDS, 9945/3, 9975/3	AML, 9801/3, 9860/3
	Refractory anaemia with ring sideroblasts	9982/3	Other MDS, 9945/3, 9975/3	AML, 9801/3, 9860/3
	Refractory anaemia with excess blasts	9983/3	Other MDS, 9945/3, 9975/3	AML, 9801/3, 9860/3
	Refractory cytopenia with multi-lineage dysplasia; Refractory cytopenia of childhood	9985/3	Other MDS, 9945/3, 9975/3	AML, 9801/3, 9860/3
	Myelodysplastic syndrome associated with isolated del(5q)	9986/3	Other MDS, 9945/3, 9975/3	AML, 9801/3, 9860/3
	Myelodysplastic syndrome, NOS	<u>9989/3</u>	Other MDS, MD/MPN	AML, 9801/3, 9860/3
	Refractory neutropenia	9991/3	Other MDS, 9945/3, 9975/3	AML, 9801/3, 9860/3
	Refractory thrombocytopenia	9992/3	Other MDS, 9945/3, 9975/3	AML, 9801/3, 9860/3

Acute myeloid leukaemia (AML) and related precursor neoplasms.	Blastic plasmacytoid dendritic cell neoplasm (see note 4)	9727/3	Other AML, 9800/3–9809/3, 9860/3
	Acute erythroid leukaemia	9840/3	Other AML, 9800/3–9809/3, 9860/3
	Acute myeloid leukaemia, NOS	<u>9861/3</u>	Other AML, 9800/3–9809/3, 9860/3, 9965/3, 9966/3, 9967/3
	Acute myeloid leukaemia with t(6;9)(p23;q34); DEK-NUP214	9865/3	Other AML, 9800/3–9809/3, 9860/3
	Acute promyelocytic leukaemia	9866/3	Other AML, 9800/3–9809/3, 9860/3
	Acute myelomonocytic leukaemia	9867/3	Other AML, 9800/3–9809/3, 9860/3
	Acute myeloid leukaemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	9869/3	Other AML, 9800/3–9809/3, 9860/3
	Acute basophilic leukaemia	9870/3	Other AML, 9800/3–9809/3, 9860/3
	Acute myeloid leukaemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) CBFβ-MYH11	9871/3	Other AML, 9800/3–9809/3, 9860/3
	Acute myeloid leukaemia with minimal differentiation	9872/3	Other AML, 9800/3–9809/3, 9860/3
	Acute myeloid leukaemia without maturation	9873/3	Other AML, 9800/3–9809/3, 9860/3
	Acute myeloid leukaemia with maturation	9874/3	Other AML, 9800/3–9809/3, 9860/3
	Acute monoblastic and monocytic leukaemia	9891/3	Other AML, 9800/3–9809/3, 9860/3
	Acute myeloid leukaemia with myelodysplasia-related changes	9895/3	Other AML, 9800/3–9809/3, 9860/3
	Acute myeloid leukaemia with t(8;21)(q22;q22) RUNX1-RUNX1T1	9896/3	Other AML, 9800/3–9809/3, 9860/3
	Acute myeloid leukaemia with t(9;11)(p22;q23); MLLT3-MLL	9897/3	Other AML, 9800/3–9809/3, 9860/3
	Myeloid leukaemia associated with Down Syndrome	9898/3	Other AML, 9800/3–9809/3, 9860/3
	Acute megakaryoblastic leukaemia	9910/3	Other AML, 9800/3–9809/3, 9860/3
	Acute myeloid leukaemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1	9911/3	Other AML, 9800/3–9809/3, 9860/3
	Therapy-related acute myeloid leukaemia	9920/3	Other AML, 9800/3–9809/3, 9860/3; 9987/3
	Myeloid sarcoma	9930/3	Other AML, 9800/3–9809/3, 9860/3
	Acute panmyelosis with myelofibrosis	9931/3	Other AML, 9800/3–9809/3, 9860/3, 9961/3
	Refractory anaemia with excess blasts in transition	9984/3	Other AML, 9800/3–9809/3, 9860/3
Therapy-related myelodysplastic syndrome	9987/3	Other AML, MDS	

Precursor lymphoid neoplasms (PLN)	B lymphoblastic lymphoma	9728/3	Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/3, 9687/3	
	T lymphoblastic lymphoma	9729/3	Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9702/3	
	B lymphoblastic leukaemia/lymphoma, NOS	<u>9811/3</u>	Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/3, 9687/3	
	B lymphoblastic leukaemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1	9812/3	Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/3, 9687/3	
	B lymphoblastic leukaemia/lymphoma with t(v;11q23); MLL rearranged	9813/3	Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/3, 9687/3	
	B lymphoblastic leukaemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)	9814/3	Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/3, 9687/3	
	B lymphoblastic leukaemia/lymphoma with hyperdiploidy	9815/3	Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/3, 9687/3	
	B lymphoblastic leukaemia/lymphoma with hypodiploidy (Hypodiploid ALL)	9816/3	Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/3, 9687/3	
	B lymphoblastic leukaemia/lymphoma with t(5;14)(q31;q32); IL3-IGH	9817/3	Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/3, 9687/3	
	B lymphoblastic leukaemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)	9818/3	Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/3, 9687/3	
	Lymphoblastic leukaemia/lymphoma, NOS	<u>9835/3</u>	Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/3, 9687/3, 9702/3	
	B lymphoblastic leukaemia	9836/3	Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/3, 9687/3	
T lymphoblastic leukaemia/lymphoma	9837/3	Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9702/3		
Mature B-cell neoplasms (MBCN), indolent	Primary cutaneous follicle centre lymphoma	9597/3	9590/3, 9591/3, 9690/3, 9691/3, 9695/3, 9698/3	
	Small lymphocytic lymphoma	9670/3	9590/3, 9591/3, 9671/3, 9689/3, 9690/3, 9691/3, 9695/3, 9699/3, 9760/3, 9761/3, 9762/3, 9800/3, 9820/3, 9823/3, 9940/3	9680/3, 9650-9655/3, 9661-9667/3
	Chronic lymphocytic leukaemia	9823/3	9590/3, 9591/3, 9670/3, 9671/3, 9689/3, 9690/3, 9691/3, 9695/3, 9699/3, 9800/3, 9820/3, 9940/3	9680/3, 9650-9655/3, 9661-9667/3
	Lymphoplasmacytic lymphoma	9671/3	9590/3, 9591/3, 9670/3, 9760/3, 9761/3, 9762/3, PCN	9680/3, 9650-9655/3, 9661-9667/3
	Waldenström macroglobulinemia	9761/3	9590/3, 9591/3, 9670/3, 9671/3, 9760/3, 9762/3, PCN	9680/3, 9650-9655/3, 9661-9667/3
	Splenic marginal zone lymphoma	9689/3	9590/3, 9591/3, 9670/3, 9699/3	9680/3
	Follicular lymphoma, NOS	<u>9690/3</u>	9590/3, 9591/3, 9597/3, 9670/3, 9691/3, 9695/3, 9698/3	9680/3, 9687/3, 9826/3, 9836/3, 9728/3, 9811/3-9818/3
	Follicular lymphoma, grade 2	9691/3	9590/3, 9591/3, 9597/3, 9670/3, 9690/3, 9695/3, 9698/3	9680/3, 9687/3, 9826/3, 9836/3, 9728/3, 9811/3-9818/3
	Follicular lymphoma, grade 1	9695/3	9590/3, 9591/3, 9597/3, 9670/3, 9690/3, 9691/3, 9698/3	9680/3, 9687/3, 9826/3, 9836/3, 9728/3, 9811/3-9818/3
	Marginal zone lymphoma	9699/3	9590/3, 9591/3, 9670/3, 9689/3	9680/3,
	Heavy chain disease	9762/3	9590/3, 9591/3, 9670/3, 9671/3, 9760/3, 9761/3, PCN	9680/3,
	Immunoproliferative small intestinal disease	9764/3	9590/3, 9591/3, 9760/3	9680/3
	Hairy cell leukaemia	9940/3	9590/3, 9591/3, 9670/3, 9800/3, 9820/3, 9823/3	9680/3
Mantle cell lymphoma	9673/3	9590/3, 9591/3, 9596/3, 9675/3, 9680/3, 9800/3, 9820/3		

**Mature B-cell neoplasms (MBCN),
aggressive**

Primary effusion lymphoma	9678/3	9590/3, 9591/3, 9596/3, 9675/3, 9679/3, 9680/3, 9684/3, 9687/3, 9688/3, 9698/3, 9712/3, 9735/3, 9737/3, 9738/3	
Primary mediastinal large B-cell lymphoma	9679/3	9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9680/3, 9684/3, 9687/3, 9688/3, 9698/3, 9712/3, 9735/3, 9737/3, 9738/3	
Diffuse large B-cell lymphoma	<u>9680/3</u>	9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9684/3, 9687/3, 9688/3, 9698/3, 9712/3, 9735/3, 9737/3, 9738/3	
Diffuse large B-cell lymphoma, immunoblastic	9684/3	9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9680/3, 9687/3, 9688/3, 9698/3, 9712/3, 9735/3, 9737/3, 9738/3	
Burkitt lymphoma	9687/3	9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9680/3, 9684/3, 9688/3, 9698/3, 9800/3, 9801/3, 9820/3, 9826/3, 9712/3, 9735/3, 9737/3, 9738/3, 9835/3	
T-cell/histiocyte rich large B-cell lymphoma	9688/3	9590/3, 9591/3, 9596/3, 9678/3, 9679/3, 9680/3, 9684/3, 9687/3, 9698/3, 9675/3, 9712/3, 9735/3, 9737/3, 9738/3	
Burkitt leukaemia	9826/3	9590/3, 9591/3, 9596/3, 9678/3, 9679/3, 9680/3, 9684/3, 9687/3, 9688/3, 9800/3, 9801/3, 9805/3-9809/3, 9820/3, 9712/3, 9735/3, 9737/3, 9738/3, 9835/3	
Follicular lymphoma, grade 3	9698/3	9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9680/3, 9684/3, 9687/3, 9688/3, 9690/3, 9691/3, 9695/3, 9712/3, 9735/3, 9737/3, 9738/3, 9597/3	
Intravascular large B-cell lymphoma (C49.9)	9712/3	9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9680/3, 9684/3, 9687/3, 9688/3, 9698/3, 9735/3, 9737/3, 9738/3	
Plasmablastic lymphoma	9735/3	9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9680/3, 9684/3, 9687/3, 9688/3, 9698/3, 9712/3, 9737/3, 9738/3, PCN	
ALK positive large B-cell lymphoma	9737/3	9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9680/3, 9684/3, 9687/3, 9688/3, 9698/3, 9712/3, 9735/3, 9738/3	
Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease	9738/3	9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9680/3, 9684/3, 9687/3, 9688/3, 9698/3, 9712/3, 9735/3, 9737/3	
B-cell prolymphocytic leukaemia	9833/3	9590/3, 9591/3, 9800/3, 9820/3, 9823/3, 9832/3	

Mature B-cell neoplasms, plasma cell neoplasms (PCN)	Solitary plasmacytoma of bone	9731/3	9671/3, 9734/3, 9735/3, 9761/3, 9762/3	9732/3; 9733/3
	Plasma cell myeloma	9732/3	9671/3, 9731/3, 9734/3, 9735/3, 9761/3, 9762/3	9733/3
	Plasma cell leukaemia	9733/3	9671/3, 9731/3, 9732/3, 9734/3, 9735/3, 9761/3, 9762/3, 9800/3, 9801/3, 9820/3,	
	Extraosseous plasmacytoma	9734/3	9671/3, 9731/3, 9735/3, 9761/3, 9762/3	9732/3; 9733/3
Mature T-cell and NK-cell neoplasms (MTCN)	Mycosis fungoides	9700/3	Other MTCN (excl. 9702/3), 9590/3, 9591/3	9702/3, 9727/3, 9729/3, 9835/3, 9837/3
	Sézary syndrome	9701/3	Other MTCN, 9590/3, 9591/3	
	(Peripheral) T-cell lymphoma, NOS	<u>9702/3</u>	Other MTCN, 9590/3, 9591/3, 9727/3, 9729/3, 9835/3, 9837/3	
	Angioimmunoblastic T-cell lymphoma	9705/3	Other MTCN, 9590/3, 9591/3	
	Subcutaneous panniculitis-like T-cell lymphoma	9708/3	Other MTCN, 9590/3, 9591/3	
	Cutaneous T-cell lymphoma, NOS	<u>9709/3</u>	Other MTCN (excl. 9702/3), 9590/3, 9591/3	9702/3, 9727/3, 9729/3, 9835/3, 9837/3
	Anaplastic large cell lymphoma, ALK positive	9714/3	Other MTCN, 9590/3, 9591/3	
	Hepatosplenic T-cell lymphoma	9716/3	Other MTCN, 9590/3, 9591/3	
	Enteropathy-associated T-cell lymphoma	9717/3	Other MTCN, 9590/3, 9591/3	
	Primary cutaneous anaplastic large cell lymphoma	9718/3	Other MTCN, 9590/3, 9591/3	
	Extranodal NK/T-cell lymphoma, nasal type	9719/3	Other MTCN, 9590/3, 9591/3	
	Systemic EBV positive T-cell lymphoproliferative disease of childhood	9724/3	Other MTCN, 9590/3, 9591/3	
	Hydroavacciniforme-like lymphoma	9725/3	Other MTCN, 9590/3, 9591/3	
	Primary cutaneous gamma-delta T-cell lymphoma	9726/3	Other MTCN, 9590/3, 9591/3	
	Adult T-cell leukaemia/lymphoma	9827/3	Other MTCN, 9800/3, 9801/3, 9805/3-9809/3, 9820/3	
	T-cell large granular lymphocytic leukaemia	9831/3	Other MTCN, 9590/3, 9591/3, 9800/3, 9820/3, 9832/3	
	T-cell prolymphocytic leukaemia	9834/3	Other MTCN, 9590/3, 9591/3, 9800/3, 9820/3, 9832/3	
	Aggressive NK-cell leukaemia	9948/3	Other MTCN, 9800/3, 9801/3, 9805/3-8909/3, 9820/3	
Hodgkin lymphoma (HL)	Hodgkin lymphoma, NOS	<u>9650/3</u>	Other HL, 9590/3, 9596/3	
	Lymphocyte-rich classical Hodgkin lymphoma	9651/3	Other HL, 9590/3, 9596/3	
	Mixed cellularity classical Hodgkin lymphoma	9652/3	Other HL, 9590/3, 9596/3	
	Lymphocyte-depleted classical Hodgkin lymphoma	9653/3	Other HL, 9590/3, 9596/3	
	Lymphocyte-depleted classical Hodgkin lymphoma, diffuse fibrosis	9654/3	Other HL, 9590/3, 9596/3	
	Lymphocyte-depleted classical Hodgkin lymphoma, reticular	9655/3	Other HL, 9590/3, 9596/3	
	Nodular lymphocyte predominant Hodgkin lymphoma	9659/3	Other HL, 9590/3, 9596/3	9680/3
	Hodgkin granuloma	<u>9661/3</u>	Other HL, 9590/3, 9596/3	
	Hodgkin sarcoma	<u>9662/3</u>	Other HL, 9590/3, 9596/3	
	Nodular sclerosis classical Hodgkin lymphoma	9663/3	Other HL, 9590/3, 9596/3	
	Nodular sclerosis classical Hodgkin lymphoma, cellular phase	9664/3	Other HL, 9590/3, 9596/3	
	Nodular sclerosis classical Hodgkin lymphoma, grade 1	9665/3	Other HL, 9590/3, 9596/3	
	Nodular sclerosis classical Hodgkin lymphoma, grade 2	9667/3	Other HL, 9590/3, 9596/3	

Histiocytic and dendritic cell neoplasms (HDCN)	Malignant histiocytosis, NOS	<u>9750/3</u>	Other HDCN	
	Langerhans cell histiocytosis	<u>9751/3</u>	Other HDCN	
	Langerhans cell histiocytosis, unifocal	<u>9752/1</u>	Other HDCN (see note 2)	
	Langerhans cell histiocytosis, multifocal	<u>9753/1</u>	Other HDCN (see note 2)	
	Langerhans cell histiocytosis, disseminated	<u>9754/3</u>	Other HDCN (see note 2)	
	Histiocytic sarcoma	<u>9755/3</u>	Other HDCN	
	Langerhans cell sarcoma	<u>9756/3</u>	Other HDCN	
	Interdigitating dendritic cell sarcoma; intermediate dendritic cell tumour	<u>9757/3</u>	Other HDCN	
	Follicular dendritic cell tumour	<u>9758/3</u>	Other HDCN	
	Fibroblastic reticular cell tumour	9759/3	Other HDCN	
Unspecified/mixed neoplasms	Lymphoma, NOS	<u>9590/3</u>	HL, MBCN, MTCN, PLN, 9591/3, 9596/3, 9760/3	
	Non-Hodgkin lymphoma, NOS	<u>9591/3</u>	MBCN, MTCN, PLN, 9590/3, 9596/3, 9760/3	
	Mixed Hodgkin lymphoma and non-Hodgkin lymphoma	<u>9596/3</u>	HL, MBCN, MTCN, PLN, 9590/3, 9591/3	
	Malignant lymphoma, mixed small and large cell, diffuse	<u>9675/3</u>	MBCN, MTCN, PLN, 9590/3, 9591/3	
	Immunoproliferative disease, NOS	<u>9760/3</u>	MBCN, 9590/3, 9591/3	
	Leukaemia, NOS	<u>9800/3</u>	9670/3, 9673/3, 9733/3, 9742/3, 9801/3-9948/3, 9963, 9964, 9965/3, 9966/3, 9967/3	
	Acute undifferentiated leukaemia; acute leukaemia, NOS	<u>9801/3</u>	9733/3, 9800/3, 9805/3, 9806/3, 9807/3, 9808/3, 9809/3, 9820/3, 9826/3, 9827/3, , 9948/3, 9965/3 9966/3, PLN, AML	
	Mixed phenotype acute leukaemia, NOS	<u>9805/3</u>	9800/3, 9801/3, 9806/3, 9807/3, 9808/3, 9809/3, 9820/3, 9826/3, 9827/3, 9860/3, , 9948/3, PLN, AML	
	Mixed phenotype acute leukaemia with t(9;22)(q34;q11.2); BCR-ABL1	9806/3	9800/3, 9801/3, 9805/3, 9807/3, 9808/3, 9809/3, 9820/3, 9826/3, 9827/3, , 9948/3, PLN, AML	
	Mixed phenotype acute leukaemia with t(v;11q23); MLL rearranged	9807/3	9800/3, 9801/3, 9805/3, 9806/3, 9808/3, 9809/3, 9820/3, 9826/3, 9827/3, 9948/3, PLN, AML	
	Mixed phenotype acute leukaemia, B/myeloid, NOS	9808/3	9800/3, 9801/3, 9805/3, 9806/3, 9807/3, 9809/3, 9820/3, 9826/3, 9827/3, 9948/3, PLN, AML	
	Mixed phenotype acute leukaemia, T/myeloid, NOS	9809/3	9800/3, 9801/3, 9805/3, 9806/3, 9807/3, 9808/3, 9820/3, 9826/3, 9827/3, 9948/3, PLN, AML	
	Lymphocytic leukaemia, NOS	<u>9820/3</u>	9670/3, 9673/3, 9733/3, 9800/3, 9801/3, 9805/3-9809/3, 9823/3-9834/3, 9940/3, 9965/3, 9966/3, 9967/3, PLN	
Prolymphocytic leukaemia, NOS	<u>9832/3</u>	9800/3, 9820/3, 9833/3, 9834/3		
Myeloid leukaemia, NOS	<u>9860/3</u>	9742/3, 9800/3, 9801/3, 9805/3, 9840/3-9931/3, 9945/3, 9946/3, 9963/3, 9964/3, 9965/3, 9966/3, 9967/3		

Note 1. In systemic mastocytosis (SM) a coexisting haematological neoplasm may be present (SM-AHNMD). Then, the disease meets the criteria for SM and the criteria for an associated, clonal haematological non-mast cell lineage disorder (MDS, MPN, AML, lymphoma or other haematological neoplasm that meet the criteria for a distinct entity in the WHO classification). This may progress/transform to acute leukaemia.

Note 2. Langerhans cell histiocytosis, irrespective of the degree of dissemination, was reclassified from /1 to /3 in the 4th edition of the WHO Classification.

Note 3. Even if the morphology codes mentioned in this table refer to the same tumour or to a transformation, there may be clinical evidence for a second tumour. In those (often rare) cases two tumours should be registered. For example, if a patient has a diagnosis of myeloma and a diagnosis of lymphoplasmocytic lymphoma, they may be considered as one disease, but they may also be two different diseases if there is clinical evidence for the latter, based on the type of immunoglobulins.

Note 4. Morphology code 9727 was used for 'Precursor cell lymphoblastic lymphoma, NOS' in ICD-O-3, while according to the 2011 ICD-O-3 Update this morphology code is used for 'Blastic plasmocytoid dendritic cell neoplasm'.